How should a patient with Down syndrome who has leukopenia, macrocytosis, erythrocytosis, and normal iron studies be managed?

Management of Down Syndrome Patient with Leukopenia, Macrocytosis, Erythrocytosis, and Normal Iron Studies

This patient requires close hematologic monitoring with serial complete blood counts every 3-4 months and consideration for bone marrow evaluation to exclude myelodysplastic syndrome, as these findings represent common but potentially concerning hematologic abnormalities in Down syndrome that warrant surveillance rather than immediate intervention.

Understanding the Laboratory Findings

The laboratory profile demonstrates three key abnormalities commonly seen in adults with Down syndrome:

• Leukopenia (WBC 2.7): Myeloid-dominant leukopenia develops as an adult Down syndrome-associated feature and becomes more pronounced with age 1, 2
• Macrocytosis (MCV 100 fL): Elevated mean corpuscular volume is frequently found among Down syndrome infants and remains elevated throughout life in two-thirds of patients 3, 4
• Erythrocytosis (Hgb 173 g/L, Hct 0.51): The elevated hemoglobin and hematocrit are notable findings that require evaluation for underlying causes 1

The iron studies (iron 30.1 μmol/L, transferrin 2.31 g/L, iron saturation 0.52, ferritin 37) are essentially normal, ruling out iron deficiency as a contributor to the macrocytosis 5.

Immediate Diagnostic Workup

Essential Laboratory Studies

Obtain the following tests to characterize the hematologic abnormalities:

• Peripheral blood smear with manual differential: Evaluate for dysplasia in erythroid, myeloid, and megakaryocytic lineages, and enumerate blasts 6, 7
• Reticulocyte count: Low or normal reticulocytes with macrocytosis suggest myelodysplastic syndrome, vitamin B12/folate deficiency, or medication effects; elevated reticulocytes would indicate hemolysis 5
• Vitamin B12 and folate levels: Macrocytosis may indicate vitamin deficiency, which is common in the general population and should be excluded 6, 5
• Red cell distribution width (RDW): Elevated RDW has the highest discriminability for detecting iron deficiency in Down syndrome patients, though current iron studies appear adequate 4
• Serum erythropoietin level: Given the erythrocytosis, measure to assess for inappropriate elevation 8, 9

Assessment for Cyanotic Heart Disease

The erythrocytosis (hemoglobin 173 g/L, hematocrit 0.51) raises concern for compensated erythrocytosis secondary to chronic hypoxemia:

• Evaluate for congenital heart disease: Adults with Down syndrome have increased prevalence of congenital heart defects that may cause chronic cyanosis 8
• Assess hydration status: Dehydration can elevate hematocrit and should be excluded before attributing erythrocytosis to other causes 8
• Check oxygen saturation: Document baseline oxygen saturation to assess for chronic hypoxemia 8

Critical caveat: If hemoglobin exceeds 20 g/dL or hematocrit exceeds 65% with symptoms of hyperviscosity (headache, poor concentration), therapeutic phlebotomy with equal volume replacement may be indicated 8. However, repeated routine phlebotomies are contraindicated due to risk of iron depletion and stroke 8.

Risk Stratification for Myelodysplastic Syndrome

Down syndrome patients have unique hematologic considerations:

Higher Risk Features Requiring Bone Marrow Evaluation

Proceed with bone marrow aspiration and biopsy if any of the following are present:

• New or worsening cytopenias: The current leukopenia and thrombocytopenia (platelet 166) warrant close monitoring 10
• Peripheral blood dysplasia or blasts: Review of blood smear is mandatory 7
• Progressive decline in blood counts: Serial CBCs showing worsening trends 10

Bone Marrow Evaluation Components

If bone marrow examination is performed, ensure the following:

• Aspirate with morphology: Evaluate dysplasia in all three lineages and enumerate blasts (≥10% dysplasia in ≥1 lineage is diagnostic for MDS) 6, 7
• Prussian blue stain for iron: Assess for ring sideroblasts 6
• Cytogenetics: Mandatory for prognostic assessment; specific abnormalities (del(5q), del(7q), +8, -7) provide presumptive evidence of MDS 6, 7
• Flow cytometry: Detect abnormalities in erythroid, myeloid, and megakaryocytic compartments 6, 7

Important consideration: Adults with Down syndrome have a 12-fold increased risk of acute lymphoblastic leukemia and 150-fold increased risk of acute myeloid leukemia in childhood, though the adult risk profile differs 11, 3, 12. Minor hematological abnormalities including leukopenia, macrocytosis, and thrombocytopenia are common in adult Down syndrome patients and may not signify underlying marrow disease 2.

Surveillance Strategy

For Stable Blood Counts Without Dysplasia

If initial workup excludes vitamin deficiency, hemolysis, and peripheral blood dysplasia:

• CBC with differential every 3-4 months initially: Determine trajectory of blood counts 10
• If stable, extend interval to every 6-12 months: Continue long-term monitoring 10
• Repeat CBC within 2-4 weeks if counts worsen: Promptly evaluate any deterioration 10
• Annual bone marrow evaluation is NOT routinely recommended: Down syndrome patients with stable blood counts and lower risk features do not require annual clinical bone marrow evaluation 10

Monitoring for Progression

Watch for the following concerning developments:

• Development of anemia: Hemoglobin <13 g/dL (men) or <12 g/dL (women) requires investigation 13
• Worsening leukopenia or thrombocytopenia: Progressive cytopenias warrant bone marrow evaluation 10
• New symptoms: Fatigue, bleeding, infections, or constitutional symptoms 6

Management of Erythrocytosis

If Secondary to Cyanotic Heart Disease

• Maintain adequate hydration: Dehydration increases viscosity and stroke risk 8
• Avoid routine phlebotomy: Only consider if hemoglobin >20 g/dL and hematocrit >65% with hyperviscosity symptoms 8
• Monitor iron status: Iron deficiency increases stroke risk even with erythrocytosis; maintain ferritin and transferrin saturation in normal range 8
• Renal protective strategies: Use caution with medications affecting renal function (ACE inhibitors, NSAIDs); consider N-acetylcysteine or bicarbonate for procedures requiring contrast 8

If No Clear Secondary Cause Identified

• Hematology consultation: Consider referral for evaluation of primary polycythemia or other myeloproliferative disorders if erythrocytosis persists without explanation 6

Specific Considerations for Down Syndrome

Unique Hematologic Features

• Macrocytosis is physiologic in many Down syndrome patients: Two-thirds maintain elevated MCV throughout life without pathologic significance 3, 4
• Thrombocytosis is common in infancy: Profound thrombocytosis from 6 weeks to 1 year of age is typical 14
• Stress erythropoiesis and dysregulated heme metabolism: Recent evidence shows lifelong dysregulation of oxygen-related processes in Down syndrome 9

When to Involve Transplant Specialist

Early consultation with a hematopoietic stem cell transplant specialist should occur if:

• Myelodysplastic syndrome is diagnosed: Allogeneic transplant may be a component of care 10
• Progressive bone marrow failure develops: Early HLA typing of patient and family members should be considered 10
• Genetic testing of potential donors is essential: Exclude carriers of germline mutations as stem cell donors 10

Avoiding Common Pitfalls

• Do not dismiss abnormalities as "just Down syndrome": While minor hematologic abnormalities are common, myelodysplastic syndrome occurs in this population and requires vigilance 2
• Do not use hemoglobin alone for screening: Macrocytosis can mask iron deficiency; use RDW combined with ferritin for optimal detection 4
• Do not perform aggressive phlebotomy: Iron depletion increases stroke risk in patients with erythrocytosis 8
• Do not delay bone marrow evaluation if counts worsen: Progressive cytopenias warrant prompt investigation 10